Use of bispecific hybrid antibodies for the development of a homogeneous enzyme immunoassay

Enzyme-labeled antibodies in bioassays

Antibody-enzyme conjugates are widely utilized in all spheres of specific analyte detection and measurement, and several trends are evident that will sustain, or even extend, this in the coming years. Of principal importance are the trends toward the development of simplified formats for the rapid and sensitive quantitation of a wide range of analytes without expensive or cumbersome instrumentation, and the exploitation of different types of enzyme and antibody molecules. Advances in hybridoma and recombinant genetics are enabling the practical manipulation of the theoretical repertoire of these reagents, facilitating their availability for a myriad of applications.

Synthesis of bifunctional antibodies for immunoassays

The synthesis of bifunctional antibodies using the principle of solid-phase synthesis is described. Two Fab' fragments were chemically linked together via a bismaleimide crosslinking reagent. The F(ab')(2) fragments from intact immunoglobulin G (IgG) were prepared using an immobilized pepsin column. Goat, mouse, and human antibodies were digested completely within 4 h. The F(ab')(2) fragments thus produced did not contain any IgG impurities. Fab' fragments were produced by reducing the heavy interchain disulfide bonds using 2-mercaptoethylamine. Use of the solid-phase reactor in the preparation of the bifunctional antibodies eliminated many of the time-consuming separation steps between the fragmentation and conjugation steps. This procedure facilitates the automation of bifunctional antibody preparation and the rapid optimization of reaction conditions.

A sensitive enzyme immunoassay of human thyroid-stimulating hormone (TSH) using bispecific F(ab')2 fragments recognizing polymerized alkaline phosphatase and TSH

Bispecific F(ab')2 fragments recognizing both human thyroid-stimulating hormone (TSH) and alkaline phosphatase (ALP) were prepared by disulfide bond exchange between F(ab')2 fragments of IgG1 monoclonal antibodies (mAbs) against TSH and ALP, and were purified to homogeneity by hydrophobic interaction HPLC. ALP was polymerized by glutaraldehyde, and a new sandwich enzyme-linked immunosorbent assay (ELISA) for TSH was developed by using the ALP polymers and bispecific F(ab')2 fragments against TSH and ALP. In this assay, the preparation of covalently linked enzyme-mAb conjugates was not needed, and the interaction of mAb with non-specific proteins was greatly reduced by the use of F(ab')2 fragments. The sensitivity for TSH was shown to increase in proportion to the degree of polymerization of ALP, and the lower detection limit obtained with the ALP trimer was 0.5 microU/ml. The sensitivity was 30 times or more higher than that of the conventional ELISA using covalently linked enzyme-mAb conjugates. The use of bispecific F(ab')2 permits the use of monomers and polymers of the signal enzyme and, thereby, regulates the sensitivity of the assay system.

Solid phase synthesis of bifunctional antibodies

Bifunctional antibodies were prepared using the principle of solid-phase synthesis. The two Fab' fragments were chemically linked together via a bismaleimide crosslinking reagent. The F(ab')2 fragments from intact IgG were prepared using an immobilized pepsin column. Goat, mouse and human antibodies were digested completely within 4 h. The F(ab')2 fragments thus produced did not contain any IgG impurities. The Fab' fragments were produced by reducing the inter-heavy chain disulfide bonds using 2-mercaptoethylamine. The use of the solid-phase reactor in the preparation of the bifunctional antibodies eliminated many of the time-consuming separation steps between the fragmentation and conjugation steps. This procedure facilitates the automation of the bifunctional antibody preparation and the rapid optimization of reaction conditions.

Chemical synthesis of bispecific monoclonal antibodies: potential advantages in immunoassay systems

To date, the applications of bispecific antibodies in immunoassay and immunocytochemical procedures have been directed at uniting two different biomolecules through the binding of epitopes on each respective substance. In this study, bispecific antibodies were constructed in which both binding sites were directed to two different epitopes of the same target molecule. Two types of bispecific antibody were constructed; a bivalent bispecific monoclonal antibody and multivalent bispecific polymers. The binding characteristics of each were investigated for changes in specificity and binding strength relative to 1:1 mixtures of parent antibodies. A bivalent bispecific antibody (BBA) was synthesised by the method of Glennie et al. (1985) from monoclonal antibodies recognising the 'M' or 'B' units of creatine kinase (CKMB). The BBA had enhanced specificity for CKMB with diminished recognition of CKMM and CKBB. A less tedious method of producing bispecific antibody involving heterobifunctional cross-linkage was used to produce multivalent bispecific antibodies (MBAs). Certain MBAs constructed to bind 'M' and 'B' units of CKMB demonstrated enhanced specificity and affinity for CKMB. MBAs were also produced to opposite ends of the 39 amino acid peptide adrenocorticotrophic hormone (ACTH). One of these demonstrated an enhanced affinity of 41-fold. We conclude that while conventional synthesis of bispecific bivalent antibodies is not a practical proposition for immunoassay development, antibodies with similar advantages can be produced with a simple method using the heterobifunctional cross-linker. The production of certain bispecific antibody combinations appears to enhance the formation of antibody-antigen matrices conferring higher binding affinities than can be achieved with an antibody mixture alone.

Antigen binding properties of highly purified bispecific antibodies

A panel of three bispecific monoclonal antibodies (bsMAbs) binding to follitropin (FSH) and to beta-galactosidase have been prepared by fusion of hybridoma cell lines resistant to oubain and neomycin. One of these bispecific antibodies contains heavy chains of the same IgG subclass, and two are composed of heavy chains of different IgG subclasses. We have investigated methods for the purification of bispecific antibodies from hybrid hybridoma supernatant fluids grown in serum-free medium. Following ammonium sulfate precipitation, bispecific antibodies can be purified in a single step by mixed mode ion-exchange HPLC on Bakerbond Abx columns. In one case, three species were resolved by ion-exchange HPLC and functional analysis showed that two peaks contained parental antibodies, and the third contained the bispecific. Ion-exchange HPLC purification of serum-free preparations from two other hybrid hybridomas resolved seven protein-containing peaks, only one of which was active in a bispecific ELISA. The equilibrium affinity constants for each of the parental antibodies for both FSH and beta-galactosidase were determined and found to be similar to those of the purified bsMAbs. Further, the association of FSH to one binding site on a bispecific antibody was shown to have no effect on the equilibrium binding constant for beta-galactosidase binding to the other site. Our results suggest that bsMAbs can be readily purified from hybrid hybridomas by a simple and rapid method, and the binding of antigen to one binding site on a bsMAb is independent of antigen binding to the second site.

Studies of the low dose 'hook' effect in a competitive homogeneous immunoassay

The interactions of two monoclonal antibodies with human growth hormone (hGH) have been investigated. The individual antibodies showed normal behavior in a competitive binding assay, but mixtures of the antibodies demonstrated a 'hook' attributable to cooperative interactions. Cooperativity was observed in titrations which preceded the competitive binding assay. Size exclusion chromatographic data suggest that the cooperativity is explained by the formation of higher molecular weight complexes (up to 700 kDa). The major complex is probably linear, consisting of three antibody molecules. Circular and linear complexes with four antibody molecules (octameric complexes) are also possible. Theoretical models also support the formation of cyclic complexes in a competitive binding assay.

Bifunctional antibodies and their potential clinical applications

Bifunctional antibodies are monovalent, bispecific, antibody-derived molecules. They have been produced by both chemical and biological means. They are thought to have several advantages over monoclonal antibodies in both immunotherapy and immunodiagnosis. Bifunctional antibodies have been shown to be efficient in the targeting of drugs, toxins, radiolabelled haptens and effector cells on to diseased tissues, primarily cancer cells. In addition, bifunctional antibodies have been used to develop novel immunoassays. The full potential of bifunctional antibodies has yet to be realised.

Bifunctional antibodies: concept, production and applications

Immunoglobulins, or antibodies, are monospecific, bivalent antigen-binding molecules. Bifunctional antibodies are bispecific, with each arm binding to a different antigen, and may be produced by biological or chemical methods. Biological production involves the fusion of two monoclonal antibody-producing hybridomas or of an immunised spleen cell and a hybridoma. The resulting hybrid hybridomas (quadromas or triomas) secrete a mixture of parenteral monoclonal antibodies and bifunctional antibody. In chemical production, the parental monoclonal antibodies can be 'chopped up and reconstituted' to produce the bifunctional antibody only. Bifunctional antibodies have a variety of potential uses. They were originally proposed as an aid to cancer chemotherapy where one of the arms of the antibody would bind to a tumour marker and the other to a drug, toxin, or cytotoxic cell. Functional agents can thus be target directly onto tumour cells, accumulating with higher density, yet with reduced side effects for the patient. Further applications have been proposed involving enzyme immobilization and novel immunoassay techniques. This review describes developments that have taken place in bifunctional antibody technology to date.